Device to accelerate drug discovery for kidney diseases

November 21, 2017, University of Cambridge
Device to accelerate drug discovery for kidney diseases
Credit: CNX OpenStax

Researchers from the Department of Engineering are collaborating with industry and academia to develop a device to improve the testing of kidney disease drugs.

State-of-the-art microfluidics technology developed by Dr Shery Huang, Lecturer in Bioengineering, and her team, will be merged with world-class expertise in induced (iPSC) technology and kidney disease from the University of Bristol, the Mario Negri Institute and Evotec.

The goal is to develop a functional and novel device – 'Nephron-on-a-Chip', also known as NEPLEX – that reflects both the filtration area as well as the resorption area of a human kidney.

Dr Huang and her lab will develop the glomerular (filter) part of the chip.

Professor Moin Saleem and his group from the University of Bristol will contribute human kidney cell lines focusing on the resorption unit, and Dr Christodoulos Xinaris and his colleagues from the Mario Negri Institute will provide human iPSC lines and expertise.

Evotec will add its state-of-the-art iPSC and platforms.

The novel device will allow testing of candidates under conditions simulating human nephrons – microscopic structures in the kidney where urine is produced – already in the pre-clinic (before clinical trials) and thereby improve and accelerate drug discovery in the field of diseases.

Dr Huang said: "I'm pleased to have this opportunity to work together with clinicians and biologists to translate our advanced engineering capability into industrial solutions. I hope this research will ultimately have a positive impact on improving health outcomes for the patient and lowering drug costs."

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "We are very pleased to have teamed up with three leading academic institutions in such an exciting area of medicine. Developing fully human and functional organotypic systems for pre-clinical drug discovery, with the possibility to include human genetics, will be a major step towards personalised and more -relevant drug candidates."

Explore further: Kidney cells made from reprogrammed stem cells lead scientists to an accurate way to screen for toxic compounds

Related Stories

Printed kidney tissue closer to reality

May 28, 2014

Queensland researchers are one step closer to printing 3D human kidney tissue thanks to a partnership between The University of Queensland and a US biotechnology company.

Recommended for you

Insect antibiotic provides new way to eliminate bacteria

November 15, 2018

An antibiotic called thanatin attacks the way the outer membrane of Gram-negative bacteria is built. Researchers at the University of Zurich have now found that this happens through a previously unknown mechanism. Thanatin, ...

Why macrophages rest in healthy tissue

November 15, 2018

ETH scientists have shown that the immune system's macrophages are regulated not only biochemically, but mechanically as well. This could explain why the cells are less active in healthy body tissue.

First microarrayed 3-D neuronal culture platform developed

November 14, 2018

Neuronal development is often regulated by the graded distribution of guidance molecules, which can either attract or repel the neuronal migration or neurite projection when presented in a format of concentration gradients, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.